S. Ahmad, E. Jenkinson, R. Carney, T. Nahu, J. Quinn, A. Dwarakanath
{"title":"P187托珠单抗在SARS-CoV-2疾病中的临床结局和治疗相关不良事件","authors":"S. Ahmad, E. Jenkinson, R. Carney, T. Nahu, J. Quinn, A. Dwarakanath","doi":"10.1136/thorax-2021-btsabstracts.296","DOIUrl":null,"url":null,"abstract":"P187 Figure 1Showing the post Tocilizumab alert card[Figure omitted. See PDF]ConclusionAppropriate treatment protocol and regular monitoring are needed for patients who receive Tocilizumab in severe SARS-CoV-2 illness. Clinicians should bear in mind the high incidence of treatment-related adverse events and the lack of data about long term effects. Treatment alert cards and specific discharge advice may be beneficial.","PeriodicalId":143926,"journal":{"name":"Fighting back: optimising treatment for COVID-19","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"P187 Clinical outcomes and treatment-related adverse events to tocilizumab in SARS-CoV-2 illness\",\"authors\":\"S. Ahmad, E. Jenkinson, R. Carney, T. Nahu, J. Quinn, A. Dwarakanath\",\"doi\":\"10.1136/thorax-2021-btsabstracts.296\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"P187 Figure 1Showing the post Tocilizumab alert card[Figure omitted. See PDF]ConclusionAppropriate treatment protocol and regular monitoring are needed for patients who receive Tocilizumab in severe SARS-CoV-2 illness. Clinicians should bear in mind the high incidence of treatment-related adverse events and the lack of data about long term effects. Treatment alert cards and specific discharge advice may be beneficial.\",\"PeriodicalId\":143926,\"journal\":{\"name\":\"Fighting back: optimising treatment for COVID-19\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Fighting back: optimising treatment for COVID-19\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/thorax-2021-btsabstracts.296\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fighting back: optimising treatment for COVID-19","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/thorax-2021-btsabstracts.296","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
P187 Clinical outcomes and treatment-related adverse events to tocilizumab in SARS-CoV-2 illness
P187 Figure 1Showing the post Tocilizumab alert card[Figure omitted. See PDF]ConclusionAppropriate treatment protocol and regular monitoring are needed for patients who receive Tocilizumab in severe SARS-CoV-2 illness. Clinicians should bear in mind the high incidence of treatment-related adverse events and the lack of data about long term effects. Treatment alert cards and specific discharge advice may be beneficial.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
